"As the industry continues its rapid pace of globalization, successful biotech companies increasingly turn to emerging markets to tap new customers, improve drug development
efficiency and locate key operations. The usual deal-making challenges are compounded when transactions take place half a world away. Managers must navigate unfamiliar (and changing) regulatory regimes, weak intellectual property and legal protections, and potentially great uncertainties around quality and supply chain integrity — on top of language and cultural differences. Panelists will share lessons from their deal experiences and apply insights from a new Ernst & Young multi-industry study, "Cross-Border Transactions in Emerging Markets," which synthesizes interviews with more than 300 transaction leaders across 15 countries."

Objective1: Prepare for the main risks and challenges presented by emerging markets.

Objective2: Understand actionable best practices and insights to help build organizational capabilities and improve deal processes.

Objective3: Learn from other industries what contributes to success and failure in emerging markets transactions.